Pomeroy Pacific together with Hadassah Australia welcomed Professor Eyal Mishani who was the keynote speaker at this month’s Boardroom Lunch.
Professor Eyal Mishani oversees the vibrant research and development programme at Hadassah. He designed and established the first Cyclotron-PET/Radiochemistry Laboratory at Hadassah/Hebrew University Hospital in Israel.
Professor Mishani is also credited with transforming Israel’s clinical diagnostic approach through the use of Fludeoxyglucose (FDG) in medical imaging. His main research aim is to develop molecular imaging methodologies to explore the in-vivo mechanism of various biochemical processes under normal and pathological conditions and translate them into imaging of diseases. Professor Mishani has five patents in the field of imaging protein tyrosine kinases and AR in cancer.
In 2010, he completed the installation of a second Cyclotron and a microPET/CT at Hadassah Hospital. In mid-2104, Professor Mishani was appointed to be the Head of the R&D division at Hadassah, the General Director of the research Fund of the Hadassah Medical Organisation (RFHMO) and a board member of Hadassit, the technology transfer company of Hadassah. Today the Fund employs 300 researchers.